Curenetics’ AI solutions for immunotherapy response prediction informed by pioneering new research partnership

Curenetics utilises AI-driven insights to predict how patients will respond to immunotherapy, supporting clinician decision-making and improving patient outcomes.

The DigitalHealth.London Launchpad company announce their latest research collaboration with the University of Pittsburgh, marking a new milestone for their immunotherapy response prediction solutions.

Curenetics is proud to announce its collaboration with the University of Pittsburgh to advance the use of artificial intelligence (AI) in healthcare. This partnership is focused on helping oncologists and their teams to understand a patient’s response to immunotherapy before cancer treatment begins. This research will ultimately support the development of personalised healthcare solutions, with the aim of improving patient outcomes through AI-driven insights.

By working closely with researchers and healthcare professionals, Curenetics is ensuring that its AI technology is built on real-world needs. The platform for immunotherapy response prediction is designed to assist in diagnosing conditions, predicting treatment responses and enhancing clinical decision-making. This powerful tool will ultimately empower medical teams to improve patient care.

On the partnership, Dr Sola Adeleke, Founder of Curenetics, said:

This is an exciting step forward in our mission to make AI a trusted and valuable partner in healthcare. By collaborating with some of the world’s leading medical institutions, we are ensuring our technology is both cutting-edge and practical, helping clinicians deliver the best possible care.

Anwaar Saeed, Associate Professor of Medicine at the University of Pittsburgh, added:

Our partnership with Curenetics represents a significant advancement in personalised healthcare. By leveraging AI to predict patient responses to immunotherapy, we are improving the way treatments are tailored, ultimately leading to better patient outcomes.

This research collaboration signals Curenetics’ ongoing commitment to work with top universities and hospitals in the UK and beyond. By contributing to global advancements in AI and health tech research, our AI-powered healthcare solutions are at the forefront of creating meaningful change for patients and the care they receive.

Curenetics is actively engaging with more universities and hospitals worldwide, expanding the reach of its technology and bringing AI-driven solutions to more healthcare settings. Visit Curenetics website to learn more about their work in AI-powered healthcare.

Curenetics is part of the seventh cohort of the DigitalHealth.London Launchpad programme.

DigitalHealth.London Launchpad is funded by the UK Government via the UK Shared Prosperity Fund (UKSPF). It is delivered by the Health Innovation Network (HIN) South London in partnership with the Office of Life Sciences, CW+, Medicity, NHS England and the Mayor of London.

For more information, please visit https://www.gov.uk/government/publications/uk-
shared-prosperity-fund-prospectus.